Skandinaviska Enskilda Banken Ab (Publ) Mersana Therapeutics, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$3.08 - $9.55 $106,762 - $331,031	34,663 Added 59.28%	93,132 $306,000
Q1 2023 May 11, 2023	SELL	$4.0 - $7.02 $11,412 - $20,028	-2,853 Reduced 4.65%	58,469 $240,000
Q4 2022 Feb 08, 2023	BUY	$5.65 - $7.86 $346,469 - $481,990	61,322 New	61,322 $359,000
Q3 2021 Nov 10, 2021	SELL	$8.56 - $14.47 $259,402 - $438,498	-30,304 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$13.28 - $18.07 $402,437 - $547,593	30,304 New	30,304 $412,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.